Company		Out Licensing Opportunities		In Licensing Opportunities		Contact

		Elliotts B Solution
		Sucraid
		Ethamolin

Home PageIn Licensing Opportunities

In Licensing Opportunities

For our Asian partners, Velos is a central source of new in-licensing opportunities.

To continue expanding our portfolio of exclusive, international licenses, Velos is constantly sourcing and screening new drugs from the U.S. and Europe. Our target project candidates must, first and foremost, address the unmet medical needs of patients in Asia. These tend to be patented, specialty NCEs, but generics that are "new" for the Asian market are also evaluated opportunistically.

We normally acquire these product licenses at the beginning of Phase III clinical trials or later to mitigate risk and maximize near-term revenue potential. Promising projects in earlier phases of clinical development are closely monitored until ready for further negotiation.

The following products in the Velos portfolio are currently available for in-licensing, with several more in the pipeline being finalized.

Focus	Product	Indication	Status
Gastroenterology	Ethamolin®	Only treatment for bleeding esophageal varices, all sizes	FDA Approved
Endocrine/ Gastroenterology	Sucraid®	Only enzyme replacement for sucrase-isomaltase disease (SID)	FDA Approved Orphan Drug
Oncology/ Neurosurgery	Elliotts B® Solution	Only synthetic cerebrospinal fluid as diluent for intrathecally injected drugs	FDA Approved Orphan Drug
Oncology	TD1	Anti-tumor agent; Colchicine derivative with improved efficacy and reduced toxicity	Preclinical

Companies seeking to license in any of these products, or to discuss additional in-licensing opportunities we are currently pursuing, please contact us at bd@velosglobal.com.